Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary

REFERENCES

1. 1.↵
   1. Wigley FM,
   2. Korn JH,
   3. Csuka ME,
   4. Medsger TA Jr,
   5. Rothfield NF,
   6. Ellman M,
   7. et al.

   Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670–7.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Merkel PA,
   2. Herlyn K,
   3. Martin RW,
   4. Anderson JJ,
   5. Mayes MD,
   6. Bell P,
   7. et al;
   8. Scleroderma Clinical Trials Consortium

   . Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002;46:2410–20.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Merkel PA,
   2. Clements PJ,
   3. Reveille JD,
   4. Suarez-Almazor ME,
   5. Valentini G,
   6. Furst DE;
   7. OMERACT 6

   . Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630–47.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Khanna D,
   2. Lovell DJ,
   3. Giannini E,
   4. Clements PJ,
   5. Merkel PA,
   6. Seibold JR,
   7. et al;
   8. Scleroderma Clinical Trials Consortium co-authors

   . Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008;67:703–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Black CM,
   2. Halkier-Sorensen L,
   3. Belch JJ,
   4. Ullman S,
   5. Madhok R,
   6. Smit AJ,
   7. et al.

   Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952–60.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Pauling JD,
   2. Shipley JA,
   3. Harris ND,
   4. McHugh NJ

   . Use of infrared thermography as an endpoint in therapeutic trials of Raynaud’s phenomenon and systemic sclerosis. Clin Exp Rheumatol 2012;30 Suppl 71:S103–15.

   OpenUrlPubMed
7. 7.↵
   1. Murray AK,
   2. Moore TL,
   3. Manning JB,
   4. Taylor C,
   5. Griffiths CE,
   6. Herrick AL

   . Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 2009;61:1103–11.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Briers JD

   . Laser Doppler and time-varying speckle: a reconciliation. J Opt Soc Am A 1996;13:345–50.

   OpenUrlCrossRef
9. 9.↵
   1. Briers JD

   . Laser speckle contrast imaging for measuring blood flow. Proceedings of the symposium on photonics technologies for 7th framework program. Opt Appl 2007:37;139–52.

   OpenUrlCrossRef
10. 10.↵
    1. Briers JD

    . Laser Doppler, speckle and related techniques for blood perfusion mapping and imaging. Physiol Meas 2001;22:R35–66.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Ruaro B,
    2. Sulli A,
    3. Alessandri E,
    4. Pizzorni C,
    5. Ferrari G,
    6. Cutolo M

    . Laser speckle contrast analysis: a new method to evaluate peripheral blood perfusion in systemic sclerosis patients. Ann Rheum Dis 2014;73:1181–5.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Della Rossa A,
    2. Cazzato M,
    3. d’Ascanio A,
    4. Tavoni A,
    5. Bencivelli W,
    6. Pepe P,
    7. et al.

    Alteration of microcirculation is a hallmark of very early systemic sclerosis patients: a laser speckle contrast analysis. Clin Exp Rheumatol 2013;31:109–14.

    OpenUrlPubMed
13. 13.↵
    1. Pauling JD,
    2. Shipley JA,
    3. Raper S,
    4. Watson ML,
    5. Ward SG,
    6. Harris ND,
    7. et al.

    Comparison of infrared thermography and laser speckle contrast imaging for the dynamic assessment of digital microvascular function. Microvasc Res 2012;83:162–7.

    OpenUrlCrossRefPubMed
14. 14.↵
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. LeRoy EC,
    2. Medsger TA Jr

    . Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Shrout PE,
    2. Fleiss JL

    . Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420–8.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Clark S,
    2. Hollis S,
    3. Campbell F,
    4. Moore T,
    5. Jayson M,
    6. Herrick A

    . The “distal-dorsal difference” as a possible predictor of secondary Raynaud’s phenomenon. J Rheumatol 1999;26:1125–8.

    OpenUrlPubMed
18. 18.↵
    1. Anderson ME,
    2. Moore TL,
    3. Lunt M,
    4. Herrick AL

    . The ‘distal-dorsal difference’: a thermographic parameter by which to differentiate between primary and secondary Raynaud’s phenomenon. Rheumatology 2007;46:533–8.

    OpenUrlAbstract/FREE Full Text